Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Evaluation of nevirapine dosing recommendations in HIV-infected children.

Foissac F, Bouazza N, Frange P, Blanche S, Faye A, Lachassinne E, Dollfus C, Hirt D, Benaboud S, Treluyer JM, Urien S.

Br J Clin Pharmacol. 2013 Jul;76(1):137-44. doi: 10.1111/bcp.12069.

PMID:
23278548
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.

Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV.

Antimicrob Agents Chemother. 2012 Oct;56(10):5374-80. doi: 10.1128/AAC.00842-12. Epub 2012 Aug 6.

PMID:
22869579
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.

Moltó J, Valle M, Miranda C, Cedeño S, Miranda J, Santos JR, Negredo E, Vilaró J, Costa J, Clotet B.

J Antimicrob Chemother. 2008 Oct;62(4):784-92. doi: 10.1093/jac/dkn268. Epub 2008 Jun 30.

PMID:
18593723
[PubMed - indexed for MEDLINE]
Free Article
4.

Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.

Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, Kolladarungkri T, Vanprapar N.

AIDS. 2005 Sep 23;19(14):1495-9.

PMID:
16135903
[PubMed - indexed for MEDLINE]
5.

Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.

Corbett AH, Hosseinipour MC, Nyirenda J, Kanyama C, Rezk NL, Mkupani P, Sichali D, Tien H, Kashuba AD, Mwansambo C, Weigel R, Kazembe P.

Antivir Ther. 2010;15(1):83-90. doi: 10.3851/IMP1488.

PMID:
20167994
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children.

Fauchet F, Treluyer JM, Frange P, Urien S, Foissac F, Bouazza N, Benaboud S, Blanche S, Hirt D.

Antimicrob Agents Chemother. 2013 Oct;57(10):4801-8. doi: 10.1128/AAC.00911-13. Epub 2013 Jul 22.

PMID:
23877688
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?

Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Chintu C, Gibb DM, Walker AS, Burger DM; CHAPAS-1 trial team.

AIDS. 2013 Aug 24;27(13):2111-5. doi: 10.1097/QAD.0b013e3283620811.

PMID:
23595153
[PubMed - indexed for MEDLINE]
8.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM.

AIDS. 2000 May 26;14(8):F77-82.

PMID:
10853971
[PubMed - indexed for MEDLINE]
9.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.

Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2011 Jun;66(6):1332-9. doi: 10.1093/jac/dkr087. Epub 2011 Mar 25.

PMID:
21441248
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, Johnson VA, Myers M, Sommadossi JP.

Antimicrob Agents Chemother. 1999 Jan;43(1):121-8.

PMID:
9869576
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.

Battegay M, Arasteh K, Plettenberg A, Bogner JR, Livrozet JM, Witt MD, Mossdorf E, Yong CL, Zhang W, Macha S, Berger F, Stern J, Robinson P, Quinson AM.

Clin Ther. 2011 Sep;33(9):1308-20. doi: 10.1016/j.clinthera.2011.08.003. Epub 2011 Aug 27.

PMID:
21872931
[PubMed - indexed for MEDLINE]
12.

Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.

Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD004772. doi: 10.1002/14651858.CD004772.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;5:CD004772.

PMID:
22786492
[PubMed - indexed for MEDLINE]
13.

Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.

Kappelhoff BS, Huitema AD, van Leth F, Robinson PA, MacGregor TR, Lange JM, Beijnen JH; 2NN Study Group.

HIV Clin Trials. 2005 Sep-Oct;6(5):254-61.

PMID:
16306032
[PubMed - indexed for MEDLINE]
Free Article
14.

Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India.

Swaminathan S, Ramachandran G, Agibothu Kupparam HK, Mahalingam V, Soundararajan L, Perumal Kannabiran B, Navaneethapandian PG, Shah I, Karunaianandham R, Sikhamani R.

J Antimicrob Chemother. 2011 Jun;66(6):1354-9. doi: 10.1093/jac/dkr075. Epub 2011 Mar 9.

PMID:
21393201
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.

Chokephaibulkit K, Cressey TR, Capparelli E, Sirisanthana V, Muresan P, Hongsiriwon S, Ngampiyaskul C, Limwongse C, Wittawatmongkol O, Aurpibul L, Kabat B, Toye M, Smith ME, Eksaengsri A, McIntosh K, Yogev R; IMPAACT P1069 Team.

Antivir Ther. 2011;16(8):1287-95. doi: 10.3851/IMP1931.

PMID:
22155910
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

King JR, Nachman S, Yogev R, Hodge J, Aldrovandi G, Hughes MD, Chen J, Wiznia A, Damle B, Acosta EP.

Pediatr Infect Dis J. 2005 Oct;24(10):880-5.

PMID:
16220085
[PubMed - indexed for MEDLINE]
17.

Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.

Ellis JC, L'homme RF, Ewings FM, Mulenga V, Bell F, Chileshe R, Molyneux E, Abernethy J, van Oosterhout JJ, Chintu C, Walker AS, Gibb DM, Burger DM.

Antivir Ther. 2007;12(2):253-60.

PMID:
17503667
[PubMed - indexed for MEDLINE]
18.

No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.

Dailly E, Billaud E, Reliquet V, Breurec S, Perré P, Léautez S, Jolliet P, Bourin M, Raffi F.

Eur J Clin Pharmacol. 2004 Jul;60(5):343-8. Epub 2004 May 20.

PMID:
15156302
[PubMed - indexed for MEDLINE]
19.

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

Pollock L, Else L, Poerksen G, Molyneux E, Moons P, Walker S, Fraser W, Back D, Khoo S.

J Antimicrob Chemother. 2009 Dec;64(6):1251-9. doi: 10.1093/jac/dkp358. Epub 2009 Oct 6.

PMID:
19812065
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.

Benaboud S, Ekouévi DK, Urien S, Rey E, Arrivé E, Blanche S, Gray G, Sim KL, Avit D, McIntyre J, Nerrienet E, Dabis F, Tréluyer JM, Hirt D; TEmAA ANRS 12109 Study Group.

Antimicrob Agents Chemother. 2011 Jan;55(1):331-7. doi: 10.1128/AAC.00631-10. Epub 2010 Oct 18.

PMID:
20956588
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk